Production (Stage)
Avalo Therapeutics, Inc.
AVTX
$3.75
-$0.16-4.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 62.79% | -253.40% | -76.60% | 181.18% | -1,384.94% |
| Total Depreciation and Amortization | 98.53% | 100.00% | 3.03% | -2.94% | -20.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -88.68% | 162.97% | 70.83% | -197.54% | 2,105.48% |
| Change in Net Operating Assets | 295.59% | 59.39% | -13.65% | -4.99% | -1,585.88% |
| Cash from Operations | 37.14% | -30.51% | 29.21% | -162.54% | -124.22% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -100.00% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | 11,562,400.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 93.27% | -- |
| Cash from Financing | -- | -- | 100.00% | -100.43% | 10,861,100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -117.96% | 556.88% | 31.20% | -116.30% | 3,816.67% |